5.0 - Summary

SUBSTANTIAL symptom improvement^* that works:

FAST^1,2

LASTS^1,2

What could MDD symptom improvement
as early as Week 1
mean for your patients?

Start with a novel mechanism of action

AUVELITY works differently–modulates both glutamatergic and monoaminergic pathways^1,3

The mechanism of action of AUVELITY in the treatment of MDD is unclear.

Rapid, significant symptom improvement
as early as Week 1, sustained at Week 6^1,2

Long-term safety and effectiveness data
measured up to 12 months^4,5

Demonstrated tolerability profile

The most common adverse events in the GEMINI 6-week study (≥5% and more than twice as frequently as placebo) were dizziness, headache, diarrhea, somnolence, dry mouth, sexual dysfunction,^† and hyperhidrosis^‡1,2

88% of all patients are covered^6§